Clinical trials: Respiratory System Disease
Respiratory Tract Infections
Collection of RNA Extracted From Nasopharyngeal and Saliva Samples From Same Patients With Suspicion of Covid-19
Constitution of a collection of SARS-CoV-2 RNA extracts from nasopharyngeal and saliva / sputum samples, from the same patients (paired samples), taken during the same consultation in an indication of detection of SARS-CoV-2 in…
- Trial name
- COLL001 (NCT04949074)
- Testing
- saliva sampling
- Where
- France
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ID Solutions
Obstructive Sleep Apnea (OSA)
INFORMing Patients With Oximetry Data to Improve MAD Engagement
Obstructive sleep apnea (OSA) is common and associated with impaired daytime functioning, reduced quality of life and increased cardiovascular, metabolic and perioperative risk.
- Trial name
- INFORM (NCT07564310)
- Testing
- Narval MRD device, MyNarval intervention (Narval CC MAD + O2 ring + MyNarval smartphone application),
- Volunteers
- 120 people
- Sponsor
- ResMed
Influenza
A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine
This prospective annual release study was designed to assess the safety of a trivalent influenza virus vaccine using a new strain recommended for the 2008-2009 influenza season not previously contained in the trivalent intranasal…
- Trial name
- MI-MA182 (NCT00677820)
- Testing
- Trivalent influenza virus vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
COVID-19
Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older
The primary objectives of the study are: To assess the safety profile of the study vaccines in each study intervention group. To assess the neutralizing antibody profile after primary series vaccination in SARS-CoV-2-naïve…
- Trial name
- NCT04762680
- Testing
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 3,159 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Allergy, Respiratory Disease
Impact of AIT on Allergic Rhinitis and Asthma
The study will assess the effectiveness of AIT treatment in real clinical practice in Germany.
- Trial name
- NCT04125888
- Testing
- Allergy immunotherapy (AIT)
- Where
- Denmark
- Volunteers
- 92,048 people
- Sponsor
- ALK-Abelló A/S
Non-Small Cell Lung Cancer
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
The primary objective of this study is to characterize the safety profile of sotorasib.
- Trial name
- NCT07143513
- Testing
- Sotorasib
- Where
- 3 sites in China
- Volunteers
- 102 people
- Sponsor
- Amgen
Obstructive Sleep Apnea
Inspire Home Study: Utilization of Home Monitoring During Therapy Optimization in Patients With an Inspire Upper Airway Stimulation System (Comparison of Home Sleep Testing vs. In-lab Polysomnography Testing)
Inspire intends to conduct this study to compare Apnea-Hypopnea Index (AHI), between the two randomization arms, at 6 months post-activation
- Trial name
- HOME (NCT04416542)
- Testing
- Home Sleep Testing
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Inspire Medical Systems, Inc.
Advanced Solid Tumor, Metastatic Solid Tumors
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET
A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Trial name
- SHIELD-1 (NCT03993873)
- Testing
- elzovantinib (TPX-0022)
- Where
- 24 sites in United States, France and 3 more
- Volunteers
- 95 people
- Sponsor
- Turning Point Therapeutics, Inc.
Cystic Fibrosis
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
This study is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of pediatric patients with Cystic Fibrosis who are 11 years…
- Trial name
- NCT01863238
- Testing
- Ophthalmologic examinations, Ivacaftor Exposed
- Where
- 38 sites in United States
- Volunteers
- 95 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Pneumonia
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
This is a single-center, randomized, placebo-controlled, double-blind, single-ascending-dose, inpatient study to assess the safety, tolerability, and pharmacokinetics of TP-271 in healthy subjects.
- Trial name
- NCT02724085
- Testing
- TP-271
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Tetraphase Pharmaceuticals, Inc
Sleep Apnea, Central, Sleep Disordered Breathing
Respicardia, Inc. Pivotal Trial of the remedē System
The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal…
- Conditions
- Sleep Apnea, Central, Sleep Disordered Breathing, Heart Failure
- Trial name
- NCT01816776
- Testing
- Treatment Group (transvenous stimulation of the phrenic nerve), Control Group (Optimal Medical Therapy)
- Where
- 30 sites in United States, Germany and 1 more
- Volunteers
- 151 people
- Sponsor
- Respicardia, Inc.
Pulmonary Disease, Chronic Obstructive
Safety, Blood Levels and Effects of GW642444
GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00469040
- Testing
- GW642444M for 14 days
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-Small Cell Lung Cancer
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
- Trial name
- ATRACT-1 (NCT00662597)
- Testing
- ASA404, carboplatin, Paclitaxel
- Where
- 248 sites in United States, Argentina and 24 more
- Volunteers
- 1,285 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Failure, Respiratory Failure
A Post Market Surveillance Study of the Hemovent Extracorporeal Cardiopulmonary Support System:The MOBYBOX Trial
The purpose of this study is to evaluate prospectively the safety and performance of the MOBYBOX System in the veno-arterial configuration in patients with cardiorespiratory failure or in the veno-venous configuration in patients…
- Conditions
- Cardiac Failure, Respiratory Failure, Cardio-Respiratory Failure, Imminent Cardiorespiratory or Respiratory Failure
- Trial name
- NCT04183660
- Testing
- MOBYBOX System
- Where
- 4 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Hemovent GmbH
Influenza
Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM
The purpose of this study is to generate additional data on the immunogenicity and safety of revaccination with Fluzone Intradermal (ID) or Fluzone Intramuscular (IM) vaccine.
- Trial name
- NCT01011049
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pulmonary Disease, Chronic Obstructive
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler®…
- Trial name
- NCT01696058
- Testing
- Tiotropium, Olodaterol
- Where
- 94 sites in United States
- Volunteers
- 1,137 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting
This is a cross-sectional study to determine the prevalence of symptomatic airway obstruction using the LFQ as a screening tool in primary care patients with a history of cigarette smoking and to provide descriptive data of this…
- Trial name
- NCT01013948
- Testing
- Non-Interventional
- Where
- 40 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection, Cross Infection
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after…
- Conditions
- Infection, Cross Infection, Bacterial Infections, Pneumonia, Ventilator-Associated
- Trial name
- NCT00965848
- Testing
- Doripenem
- Where
- 8 sites in Thailand
- Volunteers
- 270 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Post-COVID-19 Syndrome
Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome
This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.
- Trial name
- NCT05497089
- Testing
- Temelimab 54mg/kg
- Where
- 14 sites in Italy, Spain and 1 more
- Volunteers
- 203 people
- Sponsor
- GeNeuro SA
Colorectal Cancer, Breast Cancer
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
This is a phase 1 study to evaluate the safety, the Recommended Phase 2 Dose (RP2D), and preliminary efficacy of a personalized neoepitope yeast-based vaccine, YE-NEO-001, in subjects who have completed potentially curative…
- Conditions
- Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma
- Trial name
- NCT03552718
- Testing
- YE-NEO-001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NantBioScience, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.